GPC3 嵌合抗原受体 (CAR)-NK 细胞联合 Enoblituzumab 增强抗肝细胞癌疗效
GPC3 chimeric antigen receptor (CAR)-NK cells combined with Enoblituzumab enhance the anti-tumor efficacy against hepatocellular carcinoma.
肿瘤细胞治疗研究
FRONTIER PAPERS
近 5 年肿瘤细胞治疗领域的研究论文。默认按评分排序(权威性 + 新鲜度)。
GPC3 chimeric antigen receptor (CAR)-NK cells combined with Enoblituzumab enhance the anti-tumor efficacy against hepatocellular carcinoma.
共 1 条
MEMBER ACCOUNT
登录成功会直接打开下一页。